The Effectiveness of Course Therapy with Actovegin of Minimal Cognitive Dysfunction in 1st-Degree Relatives of Patients with Alzheimer’s Disease: the Role of ApoE Genotype

Abstract

The aim of the study: evaluation of the impact of long-term effects of repeated courses of Actovegin therapy on indicators of minimal cognitive dysfunction (MCD) in relatives of patients with Alzheimer’s disease (AD).Study participant: 76 people with signs of minimal cognitive dysfunction objectively confirmed by clinical and neuropsychological examination, who are relatives of the 1st degree of relatives of patients with AD.Study design: a prospective comparative study of the effects of repeated courses (4 courses in total) of three-month oral therapy with Actovegin (at a daily dose of 600 mg divided into three doses of 200 mg) every 1.5 years in groups of relatives with ApoE4(+) and ApoE4(–) genotypes.Methods: psychometric, neuropsychological, molecular genetic, statistical.Results: in the study, the effectiveness of 4 repeated courses of Actovegin therapy in relatives with manifestations of MСD was established. According to the CGI-I subscale, no deterioration was found over a period of 4 years and 9 months. By the end of the study, in 86.9% of all cases, a pronounced and moderate improvement was achieved.Conclusion: minimal cognitive dysfunction in first-degree relatives of AD patients, both in carriers of the ApoE4(–) genotype and especially in carriers of the ApoE4(+) genotype, is the basis for special attention to measures to prevent cognitive deficits.